Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Cancer Genomics and Diagnostics, Lung Cancer Treatments and Mutations, and Radiomics and Machine Learning in Medical Imaging.
Pretreatment and on-treatment ctDNA and tissue biomarkers predict recurrence in patients with stage IIIB–D/IV melanoma treated with adjuvant immunotherapy: CheckMate 915
First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
Deep computational image analysis of immune cell niches reveals treatment-specific outcome associations in lung cancer
OA04.02 CheckMate 817: First-Line Nivolumab + Ipilimumab in Patients with ECOG PS 2 and Other Special Populations with Advanced NSCLC
Abstract CT078: Tumor mutational burden (TMB) as a biomarker for clinical benefit from dual immune checkpoint blockade with nivolumab (nivo) + ipilimumab (ipi) in first-line (1L) non-small cell lung cancer (NSCLC): identification of TMB cutoff from CheckMate 568
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab
A Landscape of Pharmacogenomic Interactions in Cancer
Mutational landscape of gastric adenocarcinoma in Chinese: Implications for prognosis and therapy